RTI Cardiovascular

RTI Surgical is a leading global medical device company and contract development and manufacturing organization (CDMO) specializing in regenerative medicine and tissue-based implants. The company's cardiovascular division provides a comprehensive portfolio of human-derived tissues, including heart valves, conduits, and vascular patches, which are processed using proprietary decellularization technologies. A cornerstone of their cardiovascular offering is the SynerGraft technology, designed to remove donor cells and reduce immunogenicity while maintaining the natural extracellular matrix for better patient outcomes. These products are primarily utilized in complex surgical procedures to treat congenital heart defects and structural heart diseases. In 2020, the cardiovascular and OEM businesses were acquired by Montagu Private Equity, establishing RTI Surgical as a standalone private entity focused on tissue engineering and surgical innovation.